Radiance Biopharma

What Radiance Biopharma does

Radiance Biopharma is a privately held, clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing next-generation antibody drug conjugates (ADCs) for solid tumors. The company's lead asset, RB-601, is described as the world's first-in-human c-MET/EGFR bispecific Nano ADC, engineered at approximately half the molecular size of conventional ADCs to enable deeper tumor penetration, improved payload delivery efficiency, and reduced systemic toxicity. Initial indications targeted are non-small cell lung cancer (NSCLC) and colorectal cancer.

The company's core platform is its Nano ADC architecture, which differentiates on size and bispecific targeting rather than on a single antigen-binding ADC backbone. RB-601 is currently in Phase I/II clinical trials in China, with U.S. clinical development planned for 2026, signaling a two-region regulatory strategy aimed at addressing limitations of conventional ADCs in solid tumors. Radiance also highlights Exocellular Diagnostics' membrane Hsp70 liquid biopsy technology in its investor presentations, indicating an intent to position around a diagnostics-plus-ADC franchise.

Radiance Biopharma is pre-commercial and pre-revenue, with no disclosed pricing for its pipeline assets. The company's expected revenue model is drug development and commercialization via pharmaceutical product sales (and/or licensing) upon regulatory approval of RB-601 and future pipeline assets. Its go-to-market is event-driven, with CEO Robert K. Brooks presenting the company's pipeline at industry conferences including the World ADC London Conference and the Global Family Office Investment Summit in Miami and Dubai to reach institutional investors and family offices. The team comprises 11-50 employees led by CEO Robert K. Brooks, with A. Pockley serving in a chief scientific role.

Name

Radiance Biopharma

Website

https://radiancebio.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Radiance Biopharma is a Boston-based, clinical-stage biopharmaceutical company developing RB-601, a first-in-class c-MET/EGFR bispecific Nano ADC for solid tumors such as NSCLC and colorectal cancer, currently in Phase I/II trials in China with U.S. trials planned for 2026.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAAAAAE

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

• Antibody drug conjugates
• Oncology therapeutics
• Bispecific nano ADC
• Solid tumor treatment
• Targeted cancer therapy

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Drug Development and Commercialization: Clinical-stage biotechnology company developing next-generation Antibody Drug Conjugates (ADCs). Revenue will be generated through pharmaceutical product sales upon regulatory approval of RB-601 and future pipeline assets.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Radiance Biopharma is a clinical-stage biopharmaceutical company developing next-generation Antibody Drug Conjugates (ADCs). Its lead asset RB-601 is a first-in-class c-MET/EGFR bispecific Nano ADC engineered for solid tumors, including non-small cell lung cancer and colorectal cancer, designed for deeper tumor penetration and reduced systemic toxicity. The company is currently conducting Phase I/II trials in China with U.S. clinical development planned for 2026.

Product overview

Radiance Biopharma is a clinical-stage biotechnology company developing next-generation Antibody Drug Conjugates. The company's lead asset is RB-601, a first-in-class c-MET/EGFR bispecific Nano ADC designed for solid tumors (non-small cell lung cancer and colorectal cancer). Additionally, the company highlights Exocellular Diagnostics' membrane Hsp70 liquid biopsy technology as part of its diagnostic portfolio. RB-601 is currently undergoing Phase I/II clinical trials in China, with U.S. clinical development planned for 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• RB-601

Quantifiable outcome

• Approximately 50% smaller molecular size compared to conventional ADCs
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Exocellular DiagnosticsminorStrategic or Co-development PartnerRadiance Biopharma is associated with Exocellular Diagnostics, which developed membrane Hsp70 liquid biopsy technology. At the Miami Global Family Office Investment Summit, the company highlighted both its lead asset RB-601 and Exocellular Diagnostics' membrane Hsp70 liquid biopsy technology as part of its presentation.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Daiichi Sankyo: Japanese pharma leader and pioneer of the DXd ADC platform (Enhertu, Datroway), partnering with AstraZeneca. Sets the benchmark for ADC efficacy in solid tumors and represents the dominant competitive force in the space Radiance is targeting.
• AbbVie: Acquired ImmunoGen and its Elahere ADC franchise, adding a commercial-stage ADC to its oncology portfolio. Comparable as a major pharma incumbent that has moved aggressively into the ADC space via M&A.
• Pfizer: Acquired Seagen for $43B to anchor a major ADC franchise (Adcetris, Padcev, Tukysa, Tivdak). Comparable as a broad incumbent with a multi-asset ADC platform that competes for the same oncology indications as RB-601.
• AstraZeneca: Global pharma with the leading ADC franchise via its Enhertu/Datroway partnership with Daiichi Sankyo and a broader ADC pipeline. Comparable as a major incumbent actively developing and commercializing ADCs in NSCLC and other solid tumors.
• Gilead Sciences: Acquired Immunomedics to gain Trodelvy, the leading Trop-2-directed ADC, and is expanding its solid tumor ADC pipeline. Comparable as a large oncology player with an established ADC product and active next-generation programs.

Direct peers

• Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs), a related ADC-adjacent modality. Comparable as a small clinical-stage oncology company engineering novel antibody-based targeted therapeutics.
• ProfoundBio: Clinical-stage biotech developing ADC therapeutics for solid tumors, including bispecific ADC candidates. Highly comparable as a small private/early-public ADC company targeting overlapping solid tumor indications with novel ADC architectures.
• Mersana Therapeutics: Clinical-stage ADC developer with proprietary platforms (Dolasynthen, Immunosynthen) targeting oncology indications. Directly comparable as a similarly sized, clinical-stage biotech focused on next-generation ADC design, including payload and linker innovation.
• Tubulis: ADC platform company developing next-generation antibody-drug conjugates with proprietary conjugation chemistry and linker technology. Directly comparable as a clinical-stage ADC innovator with a focus on improving therapeutic index, similar in scale and stage to Radiance.
• Mythic Therapeutics: Clinical-stage ADC company focused on solid tumors with a next-generation antibody engineering approach. Comparable as a private clinical-stage ADC developer pursuing differentiated solid tumor strategies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Radiance Biopharma